trial · primary record
Ifinatamab Deruxtecan
Malignant Neoplasm
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 134 |
| Primary completion | 2031-08-17 |
| Primary endpoint | Part 1: Number of Participants From ≥1 Month to <12 Years Who Experience a Dose-limiting Toxicity (DLT) |
| Registry ID | NCT07630974 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:39.949Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07630974
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ifinatamab Deruxtecan · compound